Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation.

[1]  S. Tuchman,et al.  Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies , 2018, Clinical lymphoma, myeloma & leukemia.

[2]  E. Arias,et al.  Mortality in the United States, 2016. , 2017, NCHS data brief.

[3]  Shaji K. Kumar,et al.  Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. , 2017, Blood advances.

[4]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[5]  D. Dingli,et al.  Autologous stem cell transplant for multiple myeloma patients 70 years or older , 2016, Bone Marrow Transplantation.

[6]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[7]  M. Dimopoulos,et al.  Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma , 2015, Haematologica.

[8]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Joshua T. Cohen,et al.  The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. , 2015, Journal of the National Cancer Institute.

[10]  G. Colditz,et al.  High dose therapy and autologous stem cell transplant in older adults with multiple myeloma , 2015, Bone Marrow Transplantation.

[11]  H. Goldschmidt,et al.  Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years , 2015, Bone Marrow Transplantation.

[12]  A. Krishnan,et al.  Older patients with myeloma derive similar benefit from autologous transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  H. Goldschmidt,et al.  Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[15]  Stephanie J. Lee,et al.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  K. Anderson,et al.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group , 2013, Leukemia.

[17]  H. Goldschmidt,et al.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project , 2013, Leukemia.

[18]  P. Sonneveld,et al.  Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials , 2013, Haematologica.

[19]  K. Akashi,et al.  Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. , 2013, Internal medicine.

[20]  G. Morgan,et al.  A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial , 2011, Leukemia.

[21]  P. Moreau,et al.  New developments in conditioning regimens before auto-SCT in multiple myeloma , 2011, Bone Marrow Transplantation.

[22]  D. Hose,et al.  Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation , 2010, Haematologica.

[23]  D. Dingli,et al.  Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis , 2008, American journal of hematology.

[24]  A. Dispenzieri,et al.  Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma , 2007, Bone Marrow Transplantation.

[25]  W. Putten.  CART: Stata module to perform Classification And Regression Tree analysis , 2006 .

[26]  E. Jantunen,et al.  High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol , 2006, Bone Marrow Transplantation.

[27]  I. Lampert,et al.  Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients , 2006, Bone Marrow Transplantation.

[28]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[30]  S. Jagannath,et al.  Autologous stem cell transplantation in multiple myeloma patients <60 vs ⩾60 years of age , 2003, Bone Marrow Transplantation.

[31]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[32]  C. Crawley,et al.  Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients , 2003, Bone Marrow Transplantation.

[33]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[35]  R. Bouabdallah,et al.  Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma. , 2011, Hematology/oncology and stem cell therapy.

[36]  A. Palumbo,et al.  Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2) , 2004, Leukemia.